Document Detail

Pulmonary toxicity in patients receiving docetaxel chemotherapy.
MedLine Citation:
PMID:  20035385     Owner:  NLM     Status:  MEDLINE    
Pulmonary toxicity can rarely be seen with cytotoxic agents. We aimed at investigating the pulmonary toxicity of docetaxel in patients other than lung carcinoma. Forty patients were investigated prospectively. Spirometry, DLCO and high-resolution computed tomography (HRCT) scans were applied to all patients before and 14-21 days after completion of docetaxel. We used a HRCT scoring system that was based on the previous studies. We have seen no pulmonary symptoms that may reflect pulmonary toxicity. There were statistically significant differences between pre- and post-treatment values of FEV1 (L/s), FEV1/FVC (%), DLCO/VA (DLCO/L), DLCO/VA (%) (P<0.05), FEF25-75 (L/s), FEF25-75 (%) (P<0.01), DLCO (mL/mmHg/min), DLCO (%) (P<0.001), Also, there was a statistically significant difference between the pre- and post-treatment HRCT scores. There was a statistical relationship between post-treatment HRCT scores, number of docetaxel cycles (r=0.49, P<0.0001) and docetaxel cumulative dose (r=0.61, P<0.0001). Docetaxel caused a significant decline in pulmonary function tests (PFTs) and progression in HRCT scores but the symptoms of patients were not consistent with these differences. The negative effects of docetaxel on PFTs and HRCT scores should be investigated more reliably by increasing the number of patients with further studies.
Perran F Yumuk; Umut Kefeli; Berrin Ceyhan; Faysal Dane; Basak T Eroglu; Mahmut Gumus; Devrim Cabuk; Gul Basaran; Ufuk Abacioglu; Nazım S Turhal
Related Documents :
1428285 - Lung function in atrial septal defect after heart surgery.
17319045 - Fatal massive hemoptysis in a patient on low-dose oral prednisone: chronic necrotizing ...
18625615 - Geographical variation of disease manifestations in systemic sclerosis: a report from t...
3305835 - Early, aggressive open lung biopsy in heart transplant recipients.
20634145 - Repeating video/eeg monitoring: why and with what results?
16251835 - Neurological and neuropsychiatric syndromes associated with liver disease.
Publication Detail:
Type:  Journal Article     Date:  2009-12-25
Journal Detail:
Title:  Medical oncology (Northwood, London, England)     Volume:  27     ISSN:  1559-131X     ISO Abbreviation:  Med. Oncol.     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-11-24     Completed Date:  2011-04-08     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  9435512     Medline TA:  Med Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1381-8     Citation Subset:  IM    
Department of Medical Oncology, Marmara University School of Medicine, and Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / adverse effects*
Lung Diseases / chemically induced*,  physiopathology*
Middle Aged
Neoplasms / drug therapy*,  pathology
Prospective Studies
Radiation-Sensitizing Agents / adverse effects*
Respiratory Function Tests
Survival Rate
Taxoids / adverse effects*
Tomography, X-Ray Computed
Reg. No./Substance:
0/Antineoplastic Agents; 0/Radiation-Sensitizing Agents; 0/Taxoids; 15H5577CQD/docetaxel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Housing model for persons with serious mental illness moderates the relation between loneliness and ...
Next Document:  An unusual presentation of extramedullary plasmacytoma in testis and review of the literature.